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Th17 cells in human disease
Summary: Our understanding of the role of T cells in human disease is
undergoing revision as a result of the discovery of T-helper 17 (Th17)
cells, a unique CD41 T-cell subset characterized by production of
interleukin-17 (IL-17). IL-17 is a highly inflammatory cytokine with
robust effects on stromal cells in many tissues. Recent data in humans and
mice suggest that Th17 cells play an important role in the pathogenesis of a
diverse group of immune-mediated diseases, including psoriasis, rheu-
matoid arthritis, multiple sclerosis, inflammatory bowel disease, and
asthma. Initial reports also propose a role for Th17 cells in tumorigenesis
and transplant rejection. Important differences, as well as many simila-
rities, are emerging when the biology of Th17 cells in the mouse is
compared with corresponding phenomena in humans. As our under-
standing of human Th17 biology grows, the mechanisms underlying
many diseases are becoming more apparent, resulting in a new apprecia-
tion for both previously known and more recently discovered cytokines,
chemokines, and feedback mechanisms. Given the strong association
between excessive Th17 activity and human disease, new therapeutic
approaches targeting Th17 cells are highly promising, but the potential
safety of such treatments may be limited by the role of these cells in
normal host defenses against infection.
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Introduction
Two decades ago Mossman and Coffman (1) proposed that
CD41 T cells differentiate into two subsets with reciprocal
functions and patterns of cytokine secretion, termed T-helper 1
(Th1) and Th2. Th1 cells are characterized by production of
interferon-g (IFN-g) and induce cell-mediated immunity
against intracellular pathogens, while Th2 cells produce inter-
leukin-4 (IL-4) and stimulate humoral immunity against
parasitic helminths. This paradigm was maintained until
2005, when a third T-cell subset, known as Th17, was
identified (2, 3). Th17 cells are characterized by production
of IL-17 and may have evolved for host protection against
microbes that Th1 or Th2 immunity are not well suited for,
such as extracellular bacteria and some fungi. While Th17 cells
were only recently recognized as a unique Th-cell subset, IL-17
has been known for much longer. Human IL-17 was originally
cloned in 1995, and early reports demonstrated multiple
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endothelial, and fibroblastic cells (4–6). These initial studies
set the stage for much of what is now known about IL-17. The
common theme that holds true for almost every tissue is that
IL-17 mediates powerful effects on stromal cells, resulting in
production of inflammatory cytokines and recruitment of
leukocytes, especially neutrophils, thus creating a link between
innate and adaptive immunity. Although Th17 cells play an
important role in host defense, they have received considerable
attention in recent years primarily because they appear to be
the principal mediators of pathogenesis in several autoimmune
and inflammatory disorders. The discovery of Th17 cells has
opened up a new avenue for research into the etiology and
treatment of a broad spectrum of diseases. The role of Th17
cells in this diverse group of diseases is the subject of this
review.
Biology of Th17 cells
In the 3 years since Th17 cells were recognized as a unique Th
subset, data on the biology of these cells have emerged at an
astonishing pace. From these data, it is becoming increasingly
evident that both Th cell differentiation, and the cytokine
networks which control it, are remarkably complex and tightly
regulated. While work on human Th17 cells initially lagged
behind the mouse data, this gap is narrowing with the
discovery of many interesting similarities and differences
between the two species. Although many of the early principles
of mouse Th17 biology have quickly become widely accepted,
some of the most basic questions regarding human Th17 cells
are still under dispute. Given the wide array of human diseases
associated with aberrant Th17 responses and the great amount
of interest in targeted therapies, a thorough understanding of
Th17 biology in both mice and humans will clearly be essential
for designing the safest and most effective treatments.
Th17 differentiation
One of the most interesting and widely studied topics related to
Th17 cells is the nature of the signals that cause naı̈ve T cells to
differentiate along this pathway. When a naı̈ve CD41 T cell is
activated, the local cytokine milieu plays an important role in
determining which effector lineage that cell will assume, by
inducing lineage-specific transcription factors. Naı̈ve T cells
stimulated in the presence of IL-12 become Th1 cells and
express the transcription factor T-bet, while those stimulated in
the presence of IL-4 become Th2 cells and express the
transcription factor GATA-3 (reviewed in 7). Initial studies in
mice suggested that IL-23, a heterodimeric cytokine that shares
a subunit with IL-12, induced IL-17 expression (2, 3, 8, 9).
However, subsequent studies demonstrated that the IL-23
receptor is only expressed on T cells after activation, and
therefore IL-23 can upregulate IL-17 in memory T cells but
cannot act on naı̈ve T cells to induce Th17 differentiation (9).
Instead, three groups nearly simultaneously discovered that the
key to Th17 differentiation in the mouse is the combination of
transforming growth factor-b (TGF-b) and IL-6 (10–12). In
addition, tumor necrosis factor-a (TNF-a) and IL-1b can
further enhance mouse Th17 differentiation, but only in the
presence of TGF-b and IL-6 (12–14) (Table 1). This discovery
was a surprise, because TGF-b is well known to inhibit most T-
cell responses as well as to induce differentiation of forkhead
box protein 3 (FoxP3)-expressing regulatory T cells (Tregs)
(reviewed in 15). These conflicting effects of TGF-b, as an
inducer of both anti-inflammatory Tregs and pro-inflamma-
tory Th17 cells, raise a number of interesting questions about
the role of TGF-b in disease as well as the relationship between
these two very different T-cell subsets. In mice, Tregs can serve
as a source of TGF-b for naı̈ve Th17 differentiation, and one
study found that Tregs themselves can convert into Th17 cells
in the presence of IL-6 (16). Importantly, Th17 cells appear to
be resistant to the suppressive effects of Tregs (17, 18). These
results significantly complicate our current understanding of
the role of Tregs in inflammatory disease, suggesting that Tregs
may be unable to suppress Th17-mediated inflammation and
might actually augment it.
Differentiation of Th1 and Th2 cells follows similar rules in
humans as in mice; Th17 differentiation, in contrast, may not
be as conserved. IL-1b, which seems to play only a supporting
role in mouse Th17 development, is the most effective inducer
of IL-17 expression in human naı̈ve T cells. IL-6 and IL-23
induce a small amount of IL-17 alone and greatly enhance
Th17 differentiation in the presence of IL-1b (19, 20). Thus,
IL-23 and IL-1b may play a more important role in humans
than in mice, although the potential role of IL-23 in human
Th17 differentiation is still unclear, as other groups have found
IL-23 to have no effect on naı̈ve human T cells (21). In mice,
IL-23 plays an important role in Th17 effector function, but the
mechanism is still under debate. IL-23 upregulates IL-17
production and promotes survival and expansion of activated
or memory Th17 cells in vitro, although it is not absolutely
necessary (8, 12, 22). Recently, D. Cua et al. (personal
communication) reported interesting in vivo results showing
that IL-23R positive and negative Th17 cells survive and
produce IL-17 equally well, but only IL-23R-positive Th17
cells migrate to the site of inflammation in a mouse model of
multiple sclerosis (MS). Much more work is needed in both
mouse and human to fully understand how IL-23 supports
Th17-mediated pathology, especially considering that
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neutralizing antibodies targeting the shared IL-12/IL-23
subunit are already under clinical investigation in multiple
inflammatory diseases.
Another interesting topic of debate is the role of TGF-b in
human Th17 biology. Several studies have shown that TGF-b, a
crucial cytokine for mouse Th17 differentiation, actually
inhibits human Th17 development (18–20). These results
suggest that a fundamental difference between mouse and
human Th17 biology, which could be a major obstacle to
translating work from animal models into humans. There is
still significant debate in the field, though, and it is too early to
completely rule out TGF-b as an inducer of human Th17 cells.
One concern is that ‘naı̈ve’ T cells from human peripheral
blood may not be as inexperienced as those in a laboratory
mouse, which spends its life protected from exposure to
pathogens. In addition, the effects of TGF-b are extremely
concentration dependent; AY Rudensky et al. (personal
communication) found that only low doses will induce Th17
differentiation, while high doses inhibit Th17 development
and induce Tregs. This finding becomes especially important
when one considers that human T cells are more sensitive to
TGF-b than mouse T cells and that TGF-b is commonly found
in serum used in tissue culture media. A recent report by D.
Littman and colleagues found that T cells from cord blood,
which represent a more naı̈ve state than those in adult
peripheral blood, do in fact require TGF-b to differentiate into
Th17 cells (23). These results were confirmed by Volpe et al.
who found that TGF-b, IL-7b and IL-6 induced Th17
differentiation in naı̈ve human T cells from peripheral blood
(24). Additional studies are needed to resolve this debate, and
the conclusion will certainly have an impact on our
understanding of Th17 development in human disease.
Th1 and Th2 cells are known to antagonize each other, and
not surprisingly, IL-12, IFN-g, and IL-4 can inhibit Th17
differentiation in both mouse and human (2, 3, 17, 19, 20,
25, 26). IL-17, however, does not appear to inhibit Th1 or Th2
differentiation or does so very weakly, and so Th1 and Th2 cells
typically dominate over Th17 cells (14). This observation
explains one of the ways in which TGF-b can promote Th17
differentiation, by suppressing production of the inhibitory
cytokines IFN-g and IL-4, but TGF-b also has direct roles in
Th17 differentiation since it is required even in the absence of
IFN-g and IL-4 (10–12). TGF-b synergizes with IL-6 to induce
expression of the transcription factor RORgt, a key regulator of
Th17 differentiation. In mice, RORgt is both necessary and
sufficient for IL-17 expression in vitro and in vivo (27). In
humans RORC (the human ortholog of RORgt) is induced by
IL-1b, IL-6, and IL-23, the same cytokines that induce IL-17
(19, 20). In addition, RORC expression is restricted to IL-17-
producing clones (17). Thus, just as T-bet controls the Th1
lineage and GATA-3 controls the Th2 lineage, RORgt appears to
control the Th17 lineage. Still, there are a few unanswered
questions. RORgt is an orphan nuclear receptor with a ligand-
binding pocket, suggesting that its activity may be regulated by
an unknown ligand. Also, RORgt has not yet been shown to
directly bind to the IL-17 promoter, although a potential
binding site was identified (27). Despite these issues,
inhibition of RORgt may be therapeutically useful, and the
ligand-binding pocket is an ideal pharmacologic target.
In addition to RORgt, Th17 development in mice depends
on the transcription factor signal transducer and activator of
transcription 3 (STAT3), which is activated by IL-6 and IL-23.
STAT3 has multiple roles in Th17 development: in activated
Th17 cells stimulated with IL-23, it binds directly to the IL-17
promoter and induces IL-17 expression, and in naı̈ve T cells
stimulated with TGF-b and IL-6, it is required for induction of
RORgt expression, although it is not yet known if STAT3 binds
directly to the RORgt promoter (28–31). Because both RORgt
and STAT3 are required for IL-17 expression, there may be
cooperation between the two transcription factors at the IL-17
promoter. IL-23 also activates STAT4, which is the primary
mediator of IL-12 signaling and is required for Th1
Table 1. Th17 cytokine biology in mouse and human
Human Mouse




















In part (A) cytokines which have been shown to regulate the differentia-
tion or effector function of Th17 cells are listed. mm, central role in Th17
development; m, minor role in Th17 development; k, inhibitory effect on
Th17 development. In part (B) cytokines which are produced directly by
Th17 cells are listed(1 and  mean yes and no). 11, predominant
cytokine produced by Th17 cells; 1, cytokines produced by a subset of
Th17 cells; ?, insufficient data.
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differentiation, yet is still important for IL-23-induced IL-17
production (30). Thus, STAT4 may inhibit Th17 development
downstream of IL-12, while also supporting IL-17 expression
downstream of IL-23. In addition to STAT3 and STAT4, there
are likely to be other transcription factors that are required for
Th17 development, such as Smad-2 or Smad-3 downstream of
TGF-b, which may be useful therapeutic targets.
Cytokines expressed by Th17 cells
When T cells differentiate, they begin to express specific
cytokines, such as IFN-g in Th1 and IL-4 in Th2, which act in
an autocrine feedback loop to further promote differentiation,
thus giving activated T cells self-sufficiency to move out of the
lymphoid tissue and traffic to the site of inflammation while
continuing to develop. Similarly, mouse Th17 cells specifically
express IL-21 soon after activation, and autocrine IL-21 plays
an important role in RORgt and IL-17 expression. IL-21 can
also partially replace IL-6 during Th17 differentiation, giving
established Th17 cells the ability to promote further Th17
development in neighboring cells. IL-23 in combination with
TGF-b can also induce RORgt and IL-17 expression, but only
after IL-6 or IL-21 induces IL-23 receptor expression (32–36).
Thus IL-6, IL-21, and IL-23 act sequentially: first IL-6 upregu-
lates IL-21, then both IL-6 and IL-21 upregulate IL-23 receptor,
and finally IL-23 appears to upregulate effector function and
pathogenicity in Th17 cells through an unknown mechanism.
It has yet to be demonstrated what role IL-21 plays in human
Th17 differentiation, although human IL-21 has been shown
to upregulate IL-17 production and T-cell proliferation and to
counteract suppression by Tregs (37, 38).
Th17 cells are characterized by production of IL-17, but they
also produce other inflammatory cytokines, which can play an
important role in disease (Table 1). IL-17, or IL-17A, is one
member of a family of six cytokines known as IL-17A through
F. Th17 cells specifically express IL-17F in addition to IL-17A.
IL-17A and IL-17F are closely related, with 55% amino acid
identity as well as a common receptor (39). IL-17A and IL-17F
are both homodimeric cytokines, but recent evidence shows
that human and mouse T cells also produce an IL-17A/F
heterodimer that has potent inflammatory effects (40, 41).
Currently, much less is known about the inflammatory effects
of IL-17F than IL-17A, but given their high degree of similarity
and possible redundancy, it may be important to measure,
as well as to target, both IL-17A and IL-17F in disease. Other
pro-inflammatory cytokines produced by both mouse and
human Th17 cells include TNF-a, a well-known mediator of
inflammatory disease, IL-22, and IL-26 (19–21, 42–45). Much
less is known about IL-22 and IL-26, members of the IL-10
family, which promote innate, non-specific immunity
in cells outside of the immune system. Studies in keratino-
cytes and colonic myofibroblasts show that IL-22 induces
anti-microbial proteins, defensins, acute-phase proteins,
inflammatory cytokines, chemokines, and hyperplasia (46–48).
Others have found, however, that IL-22 protects hepatocytes
during acute liver inflammation (49); thus, IL-22 produced by
Th17 cells may enhance inflammation or limit tissue damage
induced by IL-17, depending on the type of tissue.
Unexpectedly, a subset of Th17 cells co-expresses IFN-g,
particularly in humans, in whom as many as half of all the
IL-171 cells also express IFN-g (19–21, 43). These double-
positive cells seem to contradict the idea that Th17 cells are a
unique subset distinct from Th1 cells, and these cells are
particularly problematic to explain, given that IFN-g has been
shown to inhibit IL-17 expression. However, human Th cell
differentiation is known to be more flexible than that in mouse,
and it is not uncommon to see IL-4/IFN-g double-positive T
cells in humans, although it is rare in mice. It is not yet clear if
these cells represent a stable phenotype or a transitional phase,
undergoing a switch from Th17 to Th1 or vice versa. Although
there are no data on the specific role of these double-positive
cells, both IFN-g and IL-17 are important mediators of
inflammation, and cells that produce both cytokines are likely
to contribute to pathogenesis in certain environments. Another
unexpected finding is the existence of many Th17 cells
co-expressing IL-10. IL-10 is an anti-inflammatory cytokine
produced by a number of different cell types. T-cell sources of
IL-10 are generally thought to include Th2 cells and various
types of Tregs, but Th1 cells have also been found to secrete
IL-10 in certain conditions and to thereby limit their own
inflammatory effects (50, 51). In mice, the combination of
TGF-b and IL-6, which synergize to induce IL-17 production,
also synergize to induce IL-10, with the end result that half
of the IL-171 cells co-express IL-10 and half of the IL-101
cells co-express IL-17 (52, 53). IL-10 produced by Th17 cells
may serve an important protective function by limiting
inflammation and tissue damage normally caused by IL-17. In
fact, Th17 cell-derived IL-10 was found to play an important
role in limiting Th17-driven inflammation in a mouse model
of MS (52). It is not yet known whether human Th17 cells ever
co-express IL-10 or what role IL-10 plays in limiting human
Th17-driven disease.
Trafficking of Th17 cells
Inflammation and pathogenesis induced by Th17 cells is a
result of the pro-inflammatory cytokines these cells produce,
but another important and often overlooked factor is the
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chemokines and chemokine receptors that mediate trafficking
of activated T cells into diseased tissue. In addition, each T-cell
subset typically expresses a unique pattern of chemokine
receptors, creating a way to specifically identify and target
different subsets. Several reports have found that human and
mouse Th17 cells express the chemokine receptor CCR6,
including memory cells from healthy peripheral blood and
inflamed tissue as well as in vitro primed naı̈ve T cells (17, 19,
43, 54). Although not all CCR61 cells are Th17 cells, it appears
that within the CCR61 population, those that co-express
CXCR3 are either Th1or IFNg-IL-17 double positive, while
those that co-express CCR4 are classical Th17 expressing only
IL-17. In addition, the majority of the RORC expression was
restricted to the CCR61CCR41 population, with a small
amount in the CCR61CXCR31 population (43). CCR6 med-
iates homing to skin and mucosal tissues and has been shown
to play an important role in recruitment of pathogenic T cells
in many inflammatory diseases now associated with IL-17,
including psoriasis, inflammatory bowel diseases (IBD), aller-
gic asthma and rheumatoid arthritis (RA) (54–58). Interest-
ingly, the CCR6 ligand CCL20 is expressed by Th17 cells and is
upregulated in stromal cells by IL-17, allowing Th17 cells in
inflamed tissues to attract additional Th17 and Th1 cells (20,
54, 59, 60). Another group found human memory Th17 cells
within the CCR21CCR5 population and Th1 cells within the
CCR21CCR51 population (61). It is not yet clear whether the
CCR61CCR41 population overlaps with the CCR21CCR5 ,
but the combination of all four markers may be a powerful tool
for isolating human Th17 cells from blood and sites of
inflammation to further characterize their biology.
We have learned a great deal about Th17 biology in a very
short period of time, including some key details: Th17 cells
differentiate in the presence of TGF-b and IL-6 in mice or IL-1b
and IL-6 in humans, depend on the transcription factor RORgt,
require IL-23 for effector function, and express the hallmark
cytokines IL-17A, IL-17F, and IL-22. Yet there are still many
unanswered questions, such as what is the exact role of RORgt
in Th17 differentiation and how does IL-23 promote Th17
pathogenicity. The relationship between Tregs and Th17 cells
as well as the possible pro-inflammatory role of Tregs are also
of great interest. A largely unexplored topic is also the role of
IL-17 production by cells other than CD41 T cells. IL-17 can
also be produced by CD81 T cells, gdT cells, and in some cases
even natural killer T (NKT) cells, neutrophils, and eosinophils.
One of the reasons Th17 cells have gained such attention is that
they are implicated in the pathogenesis of many different
animal models of disease, and therefore a critical direction for
future studies of Th17 cells will be to determine what roles
these cells play in human disease, and ultimately how useful or
safe they will be as a therapeutic target (Table 2).
Th17 cells in rheumatic diseases
Psoriasis
Psoriasis is a chronic inflammatory disease of the skin char-
acterized by epidermal hyperplasia, dermal angiogenesis, and
infiltration of monocytes, dendritic cells (DCs), and T lympho-
cytes. Evidence points to a role for both Th1 and Th17 cells in
the pathogenesis of psoriasis, due to elevated levels of many
specific inflammatory cytokines. Th1 cytokines IFN-g, IL-2,
and IL-18, as well as Th17 cytokines IL-17A, IL-17F, IL-22,
IL-26, and TNF-a (which is both a Th1 and a Th17 cytokine),
are overexpressed in serum and lesional skin (20, 47, 62, 63).
The role of IL-17 in the pathogenesis of psoriasis has been
further substantiated by increased expression of RORC, IL-6,
IL-1b, and IL-23 in psoriatic skin as compared with non-
involved skin or skin from healthy individuals (20). Some
studies have suggested that IL-15 can also induce IL-17, and it
has been shown that neutralizing antibodies to IL-15 can
improve psoriasis in a mouse model (64).
Initial studies suggested that psoriasis was a Th1 disease,
based on increased expression of the p40 subunit of IL-12.
However, many experiments have had to be re-interpreted
once it became clear that the IL-12 p40 subunit is also part of
IL-23. IL-12 consists of a p40 subunit and a p35 subunit, while
IL-23 consists of a p40 subunit and a p19 subunit. Several










Type I diabetes 1/
Autoimmune thyroiditis 1/





Inflammatory bowel disease 11
Periodontal disease 11
11, those diseases in which there is substantial and convincing evidence
for a role for Th17 cells in both humans and animal models; 1, those
diseases in which there is good evidence for a role for Th17 cells, either in
humans or animal models, but more conclusive studies are needed; 1/ ,
diseases in which there is very limited evidence suggestive of a possible
role for Th17 cells, but no conclusion can be drawn without substantial
additional work.
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studies have now shown that the p40 subunit and the IL-23-
specific p19 subunit, not the IL-12-specific p35 subunit, are
highly expressed in monocytes and DCs in psoriatic skin lesions
(20, 63, 65, 66). The role of IL-23 in the induction of dermal
changes seen in psoriasis has been confirmed by in vivo studies
done in mice. When injected into the skin of the ears, IL-23
induced epidermal hyperplasia and inflammatory cellular
infiltration similar to psoriasis, which was mediated by TNF-
a, IL-22, IL-17A, and IL-17F (42, 63).
IL-22 is elevated in blood of patients with psoriasis (47), and
IL-22R, which is expressed on epithelial cells, regulates
proliferation and differentiation of keratinocytes (46). Recent
studies have shown that IL-22 is expressed by Th17 cells and
that both IL-22 and IL-17 can induce anti-microbial peptides
commonly seen in psoriatic skin during in vitro stimulation
of primary keratinocytes (44). Also, IL-22 levels in plasma
correlated with disease severity, and IL-22 in psoriatic skin was
associated with increased expression of anti-microbial peptides
and matrix metalloproteinases (MMPs) (47). Both in vitro
derived, IL-23-differentiated Th17 cells and T cells derived
from lesional skin of patients with psoriasis induced expression
of anti-microbial peptides by normal human epithelial
keratinocytes, which was dependent on IL-17 (20). IL-23 and
IL-6, two cytokines that play a role in Th17 differentiation, also
upregulate IL-22 production by Th17 cells (42, 44). IL-17 has
been found to induce IL-6 production by human keratinocytes
and thus may initiate a positive feedback loop resulting in
amplification of both IL-17 and IL-22 responses in skin (67).
Recent studies have shown that human Th17 cells express
the chemokine receptor CCR6 as well as the CCR6 ligand
CCL20 (20, 43). This observation is important, because
peripheral blood mononuclear cells (PBMCs) from patients
with psoriasis have increased mRNA for CCR6 and skin homing
CLA1 T cells express high levels of CCR6. In addition,
lymphocytes from psoriasis patients respond to very low levels
of CCL20 and have a greater chemotactic response than those
from healthy controls (68). CCR6 and CCL20 are also markedly
upregulated in psoriatic skin lesions. Furthermore, TNF-a,
IL-1b, CD40L, IFN-g, and IL-17 can induce CCL20 expression
in cultures of primary keratinocytes, dermal fibroblasts, dermal
microvascular endothelial cells, and DCs (68).
The most compelling evidence for the role of Th17 cells in
psoriasis comes from clinical studies. Recent work found that
targeting the shared IL-12/IL-23 p40 subunit is an effective
treatment for psoriasis. A phase II study of 320 patients
with moderate-to-severe plaque psoriasis found that the
improvement in psoriasis area-and-severity index (PASI)
increased in a dose-dependent manner. At the highest dose,
81% of patients had at least 75% improvement and 52% of
patients had at least 90% improvement, as compared with 2%
of those who received placebo (69). The improvement was
associated with a decrease in the mRNA levels of several pro-
inflammatory cytokines, including the p19 subunit of IL-23
(70). The frequency of serious adverse events was slightly
higher in the treatment group versus controls but not
statistically significant. Larger studies are still needed to
determine if serious adverse events might limit the clinical
usefulness, but the results are promising. Treatments that
inhibit TNF-a are widely used in RA and are also effective in
psoriasis, with significant improvements in PASI, epidermal
hyperplasia, and inflammatory infiltrate (71). Interestingly,
a recent study found that etanercept (soluble TNF receptor)
rapidly downmodulates expression of many Th17-associated
cytokines, including IL-17, IL-22, IL-6, IL-1b, and IL-23, as
well as CCL20 and anti-microbial peptides (71). In contrast,
IFN-g and other Th1 effector molecules were not down-
regulated until very late in disease resolution. This study
suggests that Th17 cells are particularly important in driving
psoriasis, while Th1 cells may play a minor role in pathogenesis.
RA
Rheumatoid arthritis (RA) is an autoimmune disease character-
ized by chronic inflammation of synovial tissues in multiple
joints associated with bone and cartilage damage (Fig. 1). Until
recently, IFN-g was thought to be pathogenic in RA and
collagen-induced arthritis (CIA), the prototypical mouse mod-
el for RA. IFN-g is expressed in RA serum and synovial fluid,
and administration of IFN-g worsens the severity of CIA (72,
73). However, several reports in animal models point to a
protective role of IFN-g in arthritis. Mice treated with neutra-
lizing antibodies to IFN-g and IFN-g receptor-deficient mice
develop more severe arthritis than wildtype counterparts (74,
75), and IFN-g deficiency renders resistant strains of mice
susceptible to CIA (76–78). Much like psoriasis, initial studies
suggesting that CIA is Th1-mediated have recently been re-
evaluated with the discovery that the IL-12 p40 subunit is
shared by IL-23. Early studies showed that mice deficient in
p40 are protected from arthritis, but it is now clear that IL-23,
not IL-12, is required for disease. IL-23 p19-deficient mice do
not develop CIA, while IL-12 p35-deficient mice actually
develop more severe disease (79). Both IL-12 and IFN-g are
potent suppressors of Th17 differentiation in vitro, suggesting a
potential mechanism for the protective function of these
cytokines. IFN-g also regulates endogenous IL-17 responses in
vivo in animal models of RA, as arthritic mice deficient in IFN-g
or treated with neutralizing antibody to IFN-g have elevated
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Rheumatoid ArthritisInflammatory Bowel Disease
Fig. 1. Th17 cells and immune-mediated diseases. Schematic diagram showing the central role played by human Th17 cells in four types of immune-
mediated inflammatory conditions. The middle diamond represents effects that occur outside the lesions either in lymph nodes or systemically. Solid
arrows indicate proven associations, while dashed arrows indicate likely associations based on effects commonly found in other diseases. Shared features
include induction of Th17 cells by inflammatory cytokines (IL-1b, IL-6, and IL-23) elicited by dendritic cells, macrophages, osteoblasts, or brain
microglial cells, either in local lesions or in draining lymph nodes. Common effector functions of Th17-derived IL-17 and IL-22 include induction of
chemokines and pro-inflammatory cytokines from stromal cells, and stimulation of matrix metalloproteinases from macrophages and stromal cells.
Organ-specific effects such as osteoclastogenesis, disruption of the blood brain barrier, and mucus hypersecretion are described further in the text.
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IL-17 in serum and in cultures of collagen re-stimulated
spleens and lymph nodes (76, 80, S. Sarkar et al., manuscript
in preparation). Although considerable evidence suggests that
IFN-g plays a protective role in CIA by inhibiting Th17 cell
development, it may still have pathogenic effects in some
instances. For example, the effect of treating CIA with neutra-
lizing antibodies to IFN-g varies depending on the timing of
administration, demonstrating that IFN-g may be pathogenic
in the early phases of CIA but protective in the later stages (81).
In addition, the development of disease in proteoglycan-
induced arthritis in the mouse is dependent on IFN-g (82).
Similarly, there may be subsets of RA patients with Th1- or
Th17-dominant disease.
The importance of IL-17 in the pathogenesis of arthritis in
animal models has been shown quite consistently. IL-17
knockout mice develop significantly less arthritis, and
treatment with neutralizing antibodies to IL-17 or soluble
IL-17 receptor alleviates joint inflammation (83–85).
Furthermore, IL-17 receptor signaling in radiation-resistant
cells of the joint is required for the induction of chronic
destructive synovitis, cartilage damage, bone erosion, and
inflammatory cytokine expression in acute streptococcal cell
wall arthritis (86, 87). IL-17 is also required for the
development of spontaneous arthritis in other mouse models
of RA, such as IL-1Ra-deficient mice and SKG mice (88, 89).
The initial reports of the pathogenic role of IL-17 in RA were
from the laboratory of Pierre Miossec (90). His group and
others have shown that IL-17 is increased in the sera and
synovial fluid of patients with RA and is present in the T-cell-
rich areas of the synovium (90–92). Importantly, a prospective
study in RA patients showed that increased levels of IL-17 and
TNF-a mRNA expression in the synovium are predictive of
more severe joint damage progression, while high levels of
IFN-g mRNA in the joint are predictive of protection from
damage progression (93). This evidence clearly points to a role
for IL-17 in the pathogenesis of arthritis.
Further support for the role of Th17 cells in RA comes from
in vitro studies that demonstrate robust and widespread
inflammatory effects of IL-17 on cells of the joint. The
IL-17 receptor is ubiquitously expressed and initiates an
inflammatory response in many cell types important to
RA, including monocytes, macrophages, chondrocytes,
osteoblasts, and fibroblasts. IL-17 induces the production of
inflammatory cytokines such as IL-1b, TNF-a, IL-6, and IL-23
by synovial fibroblasts, monocytes, and macrophages, all of
which promote inflammation and Th17 cell development
(reviewed in 94). Thus, Th17 cells in the joint may initiate a
positive feedback loop, leading to the perpetual T-cell
activation that is thought to be critical in the generation of
autoimmunity. IL-17 also induces an array of chemokines,
including CXCL-1, -2, -5, -8, CCL-2, and CCL-20, leading to
recruitment of T cells, B cells, monocytes and neutrophils, all
of which populate the inflamed joint (reviewed in 94). SDF-1
(CXCL-12), which is present in abundance in rheumatoid
synovium and promotes recruitment of CD41 memory T
cells, monocytes, and B cells, is induced by IL-17, although
IL-1b and TNF-a are not efficient in inducing this factor (95).
The leukocyte recruitment is further enhanced by upregulation
of granulocyte colony-stimulating factor (G-CSF) and
granulocyte-macrophage colony-stimulating factor (GM-CSF),
inducers of granulopoiesis, as well as vascular endothelial
growth factor (VEGF), an inducer of angiogenesis (reviewed
in 94, 96). Clearly, IL-17 can enhance the inflammation and
cellular infiltration common in arthritis, but it can also mediate
bone and cartilage damage, which cause pain and disability in
RA patients. MMPs, nitric oxide, and receptor activator of
nuclear factor kB (RANK)/RANK ligand (RANKL), as well as
inflammatory cytokines and chemokines are upregulated in
chondrocytes and osteoblasts by IL-17. Th17 cells can induce
osteoclastogenesis indirectly by upregulating RANKL and also
directly by expressing RANKL on their cell surface (reviewed in
94, 97–99). All the above pro-inflammatory molecules are
found in RA synovium and contribute to RA pathology by
recruiting and activating inflammatory cells, maintaining the
IL-17 response, and causing destruction of tissue and bone.
TNF-a and IL-1b are overexpressed in RA and have a well-
established role in RA pathology. TNF neutralizing agents are
widely used to treat patients with RA with significant efficacy.
Several studies have shown that TNF-a and IL-1b, either
together or separately, can induce the generation of Th17 cells
(14, 19, 34), and IL-17 can induce TNF-a and IL-1b
expression by synoviocytes as well. The precise mechanisms
are still unclear, but IL-23 may be involved in the TNF-a and
IL-1b-induced secretion of IL-17 (13, 100). Such findings
provide clues to the mechanism underlying the development of
a dysregulated Th17 response in RA. IL-17 can also synergize
with TNF-a and IL-1b in mediating inflammation and joint
damage, leading some to believe that targeting IL-17 in RA
would be redundant with TNF-neutralizing therapies.
However, evidence shows that IL-17 can induce inflammation
and enhance cartilage and bone erosion in mice, even under
TNF and IL-1-neutralizing conditions (101–103). In
agreement with this, TNF blockade, along with IL-1 and IL-17
blockade, was more effective at controlling IL-6 production
and collagen degradation than blocking TNF alone in cultures
of RA synovium (60). Similarly, combination blockade of TNF
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and IL-17 suppressed ongoing CIA and was more effective than
neutralization of TNF alone (104). These results suggest that
treatments designed to block IL-17 may be beneficial in
combination with treatments that block TNF or IL-1, provided
that this approach proved to be safe. IL-17-neutralizing
therapies may also be particularly useful for the considerable
number of patients who do not respond to TNF blockade.
In addition to TNF-a and IL-1b, other cytokines involved in
Th17 biology can play a role in arthritis, further supporting the
idea that Th17 cells are key mediators of joint pathology. In
mice, Th17 cells produce IL-21, which acts to further enhance
Th17 development. While this pathway has not been examined
in human Th17 development, there are several reports which
point toward a role for IL-21 in CIA and RA. IL-21 is increased
in RA serum and synovial fluid, and its receptor is highly
expressed on peripheral blood and synovial fluid lymphocytes,
as well as synovial fibroblasts and macrophages from patients
with RA (105, 106). Administration of IL-21R fusion protein
significantly reduced disease in CIA and rat antigen-induced
arthritis (107).
IL-23, which enhances IL-17 production and Th17 effector
function in humans and mice, is also implicated in arthritis.
The role of IL-23 has been shown in CIA, where mice deficient
in the IL-23 p19 subunit developed less severe arthritis (79). In
RA patients, elevated IL-23 has been found in the sera and
synovial fluid, as well as increased expression of IL-23 p19
subunit in synovial fibroblasts (108, 109). Recently, STAT4 has
been identified as a susceptibility gene for RA (110, 111). This
is particularly interesting as STAT4, which is important in the
signaling pathway through IL-12 and IL-23 receptors, is critical
to the generation and maintenance of Th17 cells (30).
Consistent with this concept is the finding that STAT4
knockout mice were resistant to arthritis and treatment with
anti-sense STAT4 suppressed ongoing CIA (112). It is possible
that STAT4 risk alleles would enhance IL-17 responsiveness
or provide a continuous endogenous stimulation for the
maintenance of the autoimmune Th17 phenotype. Similar to
the findings in psoriasis, there is increased expression of IL-22
and IL-22R in the synovium in RA (113), but the effects of this
cytokine on cells of the joint are still unknown.
Another cytokine that may play a role in Th17 biology and
warrants further investigation is IL-15. There are some
indications that this cytokine may be involved in the
regulation of IL-17 and autoimmunity. IL-15 is overexpressed
in synovial fluid and peripheral blood T cells from RA patients
and can induce the secretion of IL-17 from PBMCs (92). Also,
RA synovial fibroblasts produce IL-15, which upregulates IL-
17 and TNF-a production by T cells. IL-17 and TNF-a then, in
turn, stimulate production of IL-15 and IL-6 by the synovial
fibroblasts, creating a positive feedback loop (114). In mice,
insertion of an IL-15 transgene on an arthritis-resistant strain
results in an increased severity of arthritis, associated with
increased IL-17 and IL-23 receptor expression (115), while
treatment with an IL-15 receptor antagonist ameliorated CIA
and downregulated TNF-a, IL-1b, IL-6, and IL-17 (116).
Our laboratory and several others have begun to characterize
the role of T cell-synovial fibroblast interactions in mediating
inflammation and tissue destruction in RA. We have shown that
IL-17 can synergize with resting T cells to stimulate RA
synovial fibroblasts to secrete IL-6, IL-8, and prostaglandin E2
(PGE2). These interactions were independent of the subset of T
cells and were seen across CD4, CD8, as well as CD45RO and
CD45RA subsets (117). We have also shown that synovial
fibroblasts readily present superantigens to resting human T
cells, which results in T-cell proliferation and is dependent on
surface molecule interactions (118).
Large numbers of T cells found in the RA synovium are
functionally distinct from resting or antigen-activated T cells
and instead resemble T cells that have been activated solely
through exposure to cytokines such as IL-6, IL-2, and TNF-a
(119). Studies done in our laboratory have shown that
cytokine-activated T cells can adhere to RA synovial fibroblasts
and induce IL-6 and IL-8 production from fibroblasts, which
was further enhanced by exogenous IL-17. Neutralization of
membrane-anchored TNF-a, which is expressed by cytokine-
activated T cells and is both upstream and downstream of IL-
17, inhibited the production of these pro-inflammatory
cytokines, which are important in mediating joint
inflammation in RA and CIA (120). We have also shown that
osteoblasts can present superantigen and induce proliferation
in T cells. The T cells can then in turn induce IL-6 production
by the osteoblasts, an effect which is augmented by IL-17
(121). Such findings provide an understanding of the in situ
stimulation of T cells, in the absence of conventional antigen-
presenting cells (APCs), in an autocrine and/or paracrine
fashion, thus maintaining the self-perpetuating chronic
inflammation seen in RA.
Understanding the regulation of Th17 cells will clearly be
important in designing therapeutic options targeting IL-17. IL-
4 is a potent suppressor of IL-17 both in vitro and in vivo. DCs
genetically modified to express IL-4 have been shown to inhibit
collagen-specific IL-17 production and reduce the incidence
and severity of CIA. The suppression mediated by the modified
DCs is robust and not reversed by exogenous IL-23, a potent
inducer of IL-17 (122, 123). Similarly, injection of an
adenoviral vector expressing IL-4 has been shown to
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ameliorate CIA by downregulating joint IL-17 levels and
reducing bone and cartilage damage (124).
There is now considerable evidence for the role of Th17 cells
in the pathogenesis of arthritis, and IL-17-targeted therapies
for RA are likely to be in use soon. Targeting IL-17 directly with
neutralizing antibodies or soluble receptors is a viable
therapeutic option, but there are also many other approaches
to limiting the Th17 response in hopes of achieving long-term
efficacy and safety. The arthritic joint presents a unique
microenvironment, whereby autocrine and paracrine positive
feedback loops mediated by TNF-a, IL-1b, IL-6, IL-23, and
possibly IL-15 promote Th17 development and inflammation.
Thus, interrupting one or more of these positive feedback
loops may limit inflammation directly as well as inhibit
maintenance and activation of Th17 cells in the joint,
hopefully without paralyzing normal immune responses.
Other rheumatological disorders
Systemic sclerosis is a connective tissue disease of unknown
etiology characterized by fibrosis of skin, lungs, and gastro-
intestinal tract. Although little is known about the pathogenesis
of systemic sclerosis, T cells infiltrate the skin and are believed
to play a role in fibroblast activation. Serum IL-17 is elevated in
these patients, especially in the early stages of the disease, and
enhances proliferation of fibroblasts as well as expression of
adhesion molecules and pro-inflammatory cytokines such as
IL-6 and IL-1. There is also increased expression of IL-17mRNA
in the skin and lung tissues (125). It has recently been
suggested that IL-21 is involved in the generation of Th17 cells
in mice (34), and studies have shown that IL-21R expression
is increased in keratinocytes from patients with systemic
sclerosis (126).
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease characterized by autoantibodies to
nuclear antigens, resulting in inflammation and damage
to multiple organs. Type I IFN plays a central role in the
pathogenesis of SLE (127), and it has been shown that type I
IFN can suppress IL-17 and IFN-g production from human
PBMCs (128). This finding makes it unlikely that IL-17 is
significant to the pathogenesis of lupus, although IL-17 is
elevated in the serum of patients with SLE (129), and
contraction of Th17 cells has been associated with
improvement in renal disease in mouse models of SLE using
tolerizing peptide (130). Recently, polymorphisms in STAT4
have been associated with increased risk for RA, but an even
stronger association was seen in patients with SLE (111). The
significance of this finding in SLE is not clear at this time, and
further understanding of T-cell cytokine biology in these
patients is required.
Reactive arthritis (ReA)/undifferentiated spondyloarthropathy
(uSpA) is an inflammatory joint disorder that is typically
triggered by infection. ReA/uSpA is often a self-limiting
disease, but 20% of patients with ReA develop chronic
arthritis. Data on relative cytokine concentrations in ReA/
uSpA are limited and contradictory, with some evidence for
a predominance of Th1 cytokines and some evidence for a
predominance of immunosuppressive cytokines. However,
a recent report found that IL-17, IL-6, TGF-b, and IFN-g are
all elevated in ReA/uSpA synovial fluid as compared with RA,
suggesting that both Th1 and Th17 cells may play a role in
pathogenesis (131).
Th17 cells in non-rheumatic autoimmunity
MS
Pro-inflammatory cytokines have long been suspected in the
induction and pathogenesis of MS (Fig. 1) (132). Most of these
early studies found that expression of IL-6, IFN-g, TNF-a, and
IL-1b, primarily attributed to monocytes, microglial cells, and
astrocytes, was correlated with active MS (133–135). Not until
1999 was the presence of elevated levels of mRNA for IL-17
detected in the blood and cerebrospinal fluid (CSF) of MS
patients (136). We now know that the development of human
Th17 cells is dependent on IL-1b and IL-6, thus supporting a
role for glial cells and brain-infiltrating monocytes/macro-
phages in driving the pathogenic T-cell response in MS. Despite
the demonstration of elevated IL-17 in serum and CSF of MS
patients, very few experiments have been performed to analyze
the functional importance of IL-17 in human demyelinating
disease. However, several studies using the experimental auto-
immune encephalomyelitis (EAE) model in mice have sug-
gested that IL-17 may be a critical pathogenic factor in MS.
Like many other autoimmune diseases, EAE was previously
thought to be a Th1-cell-mediated disease. However,
immunization of IL-12 receptor-b2-deficient mice with the
encephalitogenic peptide of myelin oligodendrocyte (MOG)
protein resulted in more rapid development of paralysis and
increased inflammation of the central nervous system (137).
Elevated levels of IL-23 p19 mRNA expression were detected
in splenocytes of MOG-immunized IL-12 receptor-deficient
mice, and antigen-restimulated splenocytes of knockout mice
produced more IL-17 and TNF-a while producing less IFN-g
(137). In a reciprocal study, utilizing IL-23p19-deficient mice,
EAE induction was completely abrogated despite a similar
influx of immune cells into the CNS compared with wildtype
mice that developed EAE (8). The CNS-infiltrating CD41 T cells
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in IL-23p19/ mice expressed IFN-g at levels comparable
with wildtype mice, but they completely lacked expression of
IL-17, TNF-a and IL-6 when restimulated with MOG peptide in
vitro (8). The production of IL-17 by encephalitogenic antigen-
activated CD41 T cells was enhanced by addition of IL-23 to
cell cultures, and these Th17 cells were sufficient to induce EAE
upon adoptive transfer into a susceptible strain of mice (8).
Spontaneous IL-23 expression was significantly elevated in
human monocyte-derived DC (mDCs) isolated from the
peripheral blood of MS patients compared with healthy
control subjects (138). While transfection with anti-sense IL-
23 oligonucleotides did not affect major histocompatibility
complex (MHC) class II or costimulatory molecule expression
on mDCs, supernatants of such mDCs contained lower
amounts of IL-23 and were ineffective at inducing IL-17 from
purified human CD41 cells compared with supernatants from
control mDCs (138). The ability of mDCs from MS patients to
stimulate Th17 cells was enhanced by prior bacterial
lipopolysaccharide (LPS) treatment of the mDCs, and, in a
separate study, mDCs isolated from MS patients with an active
bacterial infection were more potent stimulators of IL-17 and
IFN-g than mDCs from non-infected MS patients or patients
with bacterial meningitis (138, 139). The role of mDCs in the
induction of Th17 cells reactive to myelin antigens was further
substantiated in the mouse EAE model (140). In mice
immunized with encephalitogenic antigens, administration of
an anti-IL-23 neutralizing antibody delayed and diminished the
onset of disease while also decreasing the severity of EAE
(141). This therapeutic effect of anti-IL-23 antibody was
more profound than treatment with anti-IL-17 antibodies,
possibly due to differential effects on the influx of IFN-g and
TNF-a-producing CD41 T cells into the CNS, suppression of
epitope spreading, or effects of anti-IL-23 on production of
other Th17 cytokines (141). Thus, inhibition of Th17 cell
activity by means of IL-23 neutralization may be an effective
strategy for treating MS. Another potential treatment strategy in
MS could involve the in vivo induction or administration of IL-
27, a natural inhibitor of the generation of Th17 cells in mice,
but the role of IL-27 in regulating human Th17 cells needs
further examination (142, 143).
The functional properties of IL-17 in the neuropathology of
MS are just beginning to be elucidated. A comparison of Asian
patients with opticospinal MS versus conventional MS and
control subjects showed increased levels of IL-17 and IL-8 in
the CSF of the patients with the more severe, opticospinal form
of the disease (144). Levels of IL-17 and IL-8 correlated with
the extent of spinal cord inflammation measured by magnetic
resonance imaging and the leakage of albumin into the CSF
(144). Autopsied spinal cord tissue showed a remarkable influx
of neutrophils and severe damage to myelin and axons at the
cornu laterale of the thoracic spinal cord (144). A recent study
showed that human CD41 T cells differentiated toward a Th17
phenotype could more effectively traverse through a layer of
blood brain barrier endothelial cells (BBB-EC) than their Th1-
differentiated counterparts (145). These human Th17-
polarized cells expressed either IL-17 (23.2% of total
CD41CD45RO1 cells), IL-22 (7.3%), or both (17.5%), and
the IL-171IL-221 cells preferentially expressed granzyme B
and killed neuronal cells isolated from the CNS of human
fetuses (145). Cultured human BBB-EC, as well as endothelium
in biopsied CNS material from MS patients, expressed IL-17
and IL-22 receptors (145). Human BBB-EC expressed lower
levels of the tight junction proteins Occludin and ZO-1
following culture with recombinant human IL-17 but not IL-
22, yet both IL-17 and IL-22 pretreatment of a monolayer of
BBB-EC enhanced the transmigration of freshly isolated human
peripheral blood CD41 T lymphocytes (145). Taken together,
these data suggest that one role of Th17 cells in MS is to weaken
the BBB, allowing the influx of serum albumin, CD41
T lymphocytes, and neutrophils, attracted by elevated IL-8
in the CSF. In diseases such as RA, IL-17 is recognized as a
stimulator of MMP expression, and there is a strong association
between MMPs, BBB dysfunction, and neuronal apoptosis in
MS (146, 147). However, no direct role of IL-17 on the
expression of MMPs in the brain or spinal cord has been
established. Much further work is needed to characterize these
and other effects of IL-17 and IL-22 on human brain
endothelial cells, astrocytes, and microglial cells in MS.
Other autoimmune diseases
Autoimmune myocarditis is generally attributed to an immune
reaction toward cardiac myosin following heart infections and
is the leading cause of heart failure in young adults (148).
Findings that mice lacking the Th1-associated transcription
factor T-bet were more susceptible than wildtype mice to
experimental autoimmune myocarditis led to the discovery
that these mice had elevated IL-23 and IL-17 production (149).
Experimental myocarditis was reduced by in vivo neutralization
of IL-17 (149, 150). Very recently, it was shown that IL-17
stimulated primary human cardiac fibroblasts to express MMP-
1, MMP-2, MMP-9, and MMP-13, suggesting that IL-17 may
play a significant role in fibroblast migration into the inflamed
heart and cartilage breakdown (151).
Endometriosis results from the growth of uterine glandular
epithelial cells and stromal cells in the peritoneal cavity and is
often considered an autoimmune phenomenon based on the
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production of autoantibodies (152). The production of anti-
laminin antibodies in association with endometriosis is a
significant risk factor for infertility and miscarriages within
the first trimester of pregnancy (153). A study of 62 women
undergoing laparoscopic surgery for infertility, abdominal
pain, pelvic mass, or tubal sterilization revealed that 36
women had evidence of endometriosis, and among these, the
women with infertility (n = 17) had significantly elevated IL-17
levels in their peritoneal fluid compared to women without
endometriosis or women with endometriosis without
infertility (154).
Vogt–Koyanagi–Harada (VKH) disease is an autoimmune
disease associated with immune attack of melanocytes result-
ing in diffuse granulomatous panuveitis and systemic
manifestations including alopecia, vitiligo, poliosis, and
central nervous system disorders (155). IL-23 was elevated in
the serum of VKH patients that had active uveitis compared
with healthy controls, whereas no elevation in IL-23 was
detected in VKH patients without active uveitis (156).
Similarly, peripheral blood CD41 T cells from VKH patients
with active uveitis produced higher levels of IL-17 when
stimulated with anti-CD3 and anti-CD28 antibodies than
T cells from healthy controls or VKH patients without
uveitis (156). Experimental autoimmune uveitis elicited by
immunization of mice with interphotoreceptor retinoid-
binding protein resulted in the production of antigen-specific
CD81 T cells producing IL-17 that were capable of transferring
disease (157). In humans with non-VKH uveitis, Th17 cells
were found in the peripheral blood at levels directly correlating
to disease activity (25). Interestingly, these human Th17 cells
from uveitis patients were expanded in the presence of human
IL-2 and inhibited by IFN-g (25).
Despite established associations between the autoimmune
endocrine diseases, such as type I diabetes and autoimmune
thyroiditis, and Th17-associated cytokines IL-1b, IL-6, and
TNF-a, there has been relatively little attention given to the role
played by Th17 cells in endocrine autoimmunity (158–160).
In a subdiabetogenic model of type I diabetes in mice, daily
injections of IL-23 led to increases in pancreatic IL-17, IFN-g,
TNF-a, and IL-18 that correlated with increased cellular
infiltration, islet apoptosis, and hyperglycemia (161).
Polymorphisms in the genes for IL-1b, IL-1RA, IL-6, and
TNF-a were studied in cohorts of Hashimoto’s thyroiditis
patients and healthy controls, and among these, only the
polymorphism C/G in the IL-6 promoter region ( 572) was
shown to be statistically significant in thyroiditis patients.
One study has demonstrated that blockade of TNF-a in
granulomatous experimental autoimmune thyroiditis resulted
in the resolution of chronic lesions that was coincident with a
decrease in IL-17 and other pro-inflammatory cytokines (162).
While suggestive that Th17 cells may also play a role in diabetes
and thyroiditis, these studies need to be followed-up with well-
controlled human studies before advancing the idea that
endocrine autoimmunity is Th17 mediated (163).
Th17 cells in asthma and allergic diseases
Asthma
The above correlations between the presence of IL-17A and
cell-mediated autoimmune diseases that were traditionally
thought to be Th1 dependent might lead one to conclude that
IL-17 is not involved in Th2-mediated inflammation. However,
there is significant evidence that suggests an important role for
IL-17 in the pathogenesis of allergies and asthma (Fig. 1).
Sputum samples from asthmatic patients have been shown by
several independent groups (164–166) to contain elevated
levels of IL-17 compared with control subjects. Patients with
allergic asthma also had elevated levels of IL-17 in plasma
compared with non-asthmatic control subjects (167),
although this study did not have enough participants to reach
statistical significance. More direct evidence that Th17 cells
contribute to allergic asthma in humans comes from a study of
Dermatophagoides farinae (Df)-restimulated T-cell clones from the
peripheral blood of atopic asthmatic patients (168). Although
mitogenic stimulation of PBMCs using anti-CD3 and anti-
CD28 antibodies induced equivalent levels of IL-17 from
control subjects, non-atopic asthmatics, and allergic asth-
matics, only the asthmatic patients produced IL-17 following
Df-mediated activation (168).
IL-17 is thought to have several functions in the lung, as well
as systemically, to promote allergic asthma. Human bronchial
fibroblast cells respond to stimulation with IL-17 in vitro by
producing IL-6, IL-8, and GRO-a (164). IL-8 and GRO-a are
known chemoattractants for neutrophils, and IL-6 is a
neutrophil-activating cytokine (169). Thus, the increased
expression of IL-17 in the lung during asthma may explain
the increased accumulation and activation of lung neutrophils.
Similarly, cultured human airway smooth muscle cells
produced IL-8 and IL-6 upon activation with IL-17, and the
production was enhanced by IL-1b and TNF-a, respectively
(170, 171). Similarly, eotaxin-1 (CCL11) was produced by
human airway smooth muscle cells cultured with IL-17, an
effect that was cooperative with induction by IL-1b (172).
Cooperative effects between IL-17 and TNF-a were also
detected in the stimulation of IL-8 and IL-6 production by
human lung epithelial cells (173). In addition to its local and
systemic effects on neutrophils, IL-17, acting through
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stimulation of IL-6, was also shown to induce the expression of
the mucin genes, MUC5B and MUC5AC, by human bronchial
epithelial cells (174). Surprisingly, the Th2 cytokines IL-4, IL-
9, and IL-13 did not have the same effect on human bronchial
epithelial cells (174).
The production of IL-17 is primarily attributed to CD41 T
cells, and T-cell clones derived from PBMCs of atopic asthma
patients produced IL-17 upon restimulation with Df extract
(168). Interestingly, the production of IL-17 was not restricted
to CD41 Th cells in the sputum and bronchial alveolar lavage
(BAL) of asthmatic patients, but IL-17 was also detected in
airway eosinophils by immunocytochemistry (164).
The accumulated evidence suggests that IL-17 plays an
important pathologic role in the development of allergies and
asthma. This presents the possibility that interfering with the
activity of Th17 cells or IL-17 could be an effective treatment
modality (175). In vitro studies have shown that glucocorticoids
can interfere with the induction of cytokines and chemokines
by human bronchial fibroblasts and epithelial cells (164, 169),
and one study demonstrated that oral corticosteroid treatment
reduced the levels of IL-17 detected by immunocytochemistry
in bronchial biopsy specimens (176).
Atopic dermatitis and contact hypersensitivity
In addition to the role played by Th17 cells in allergic asthma
and psoriasis, emerging evidence suggests that IL-17-produ-
cing T cells are also involved in the pathogenesis of atopic
dermatitis and contact hypersensitivity (177, 178). As is the
case with most autoimmune diseases and asthma, the incidence
of atopic dermatitis, a chronic inflammatory disease of the
skin, is increasing in developed countries (179). Genetic as
well as environmental factors are thought to be critical to
disease etiology and atopic dermatitis, which usually begins
during childhood, often precedes development of atopic
rhinitis and asthma in susceptible individuals (179). Immuno-
histochemical analysis of acute and chronic lesions from atopic
dermatitis patients revealed that IL-17 was preferentially asso-
ciated with acute atopic dermatitis but not the chronic skin
specimens (180). The cellular source of IL-17 in atopic
dermatitis skin lesions was not evaluated.
Contact hypersensitivity is an allergen-induced skin
inflammatory reaction mediated by CD81 T cells that was
traditionally associated with IFN-g-producing Tc1 cells.
However, neutralization of IL-17 was effective at suppressing
contact hypersensitivity in DNFB-treated mice while blockade
of IFN-g was ineffective (181). Interestingly, CD81 T cells
were the main producers of IL-17 in this model system, and
blockade of IL-17 led to decreased levels of IL-1a, IL-1b, IL-6,
and IFN-g in the sensitized ear tissue (181). Blockade of the
voltage-gated potassium channel, Kv1.3, which has been
shown to be expressed by effector-memory T cells in
autoimmunity, inhibited hapten-induced allergic contact
dermatitis in a rat model (182, 183). The inhibition of
allergic contact dermatitis correlated with decreased
infiltration of the skin by CD81 T cells and reduced levels of
IL-17, IL-2, and IFN-g (183). Studies in human skin
inflammation are limited, but it was demonstrated that nickel-
elicited human CD41 T cells simultaneously produced IL-17,
IFN-g, and TNF-a (184). Recombinant IL-17 induced
production of IL-8 from human keratinocytes, both directly
and synergistically with IFN-g and TNF-a (184). Thus, IL-17
production seems to be a common feature in skin
inflammation not only in psoriasis patients but also when
induced by allergens. It will be interesting to determine if
treatment of atopic dermatitis and contact hypersensitivity by
corticosteroids or the topical calcineurin inhibitors, tacrolimus
ointment, or pimecrolimus cream, result in decreased IL-17
production by skin-infiltrating CD41 and CD81 T cells (179).
Th17 cells in other immune-mediated diseases
IBD
As in other inflammatory diseases that attack self-tissues, IL-23
and Th17 cells are emerging as the prime targets for disease
intervention in the inflammatory bowel disease (IBD), specifi-
cally Crohn’s disease and ulcerative colitis (185) (Fig. 1).
Several studies in both spontaneous and bacteria-induced
mouse models of IBD have established that IL-23, but not IL-
12, is an essential cytokine for intestinal inflammation (22,
186, 187). These data in mice shed new light on the mechan-
ism of clinical remission of Crohn’s disease mediated by
antibodies against the p40 subunit shared by IL-12 and IL-23
(188). A recent large cohort study in European populations of
differing ethnicities described a single nucleotide polymorph-
ism in the IL-23 receptor (Arg381Gln) that is significantly
associated with both Crohn’s disease and ulcerative colitis
(189). New orally administered drugs that inhibit both IL-23
and IL-12 are currently being tested for clinical efficacy against
Crohn’s disease in Phase I and II trials with promising results
thus far (190, 191).
Although still under intense investigation in humans, mouse
Th17 cells do not require IL-23 for early commitment to the
Th17 lineage, but rather utilize IL-23 to sustain IL-17
production and promote effector function (21). Early human
Th17 development is currently believed to rely on the
inflammatory cytokines IL-1b and IL-6 (19, 20). Human IL-
1b and IL-6 have long been identified as mediators of intestinal
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inflammation, their production along with TNF-a being
mainly attributed to activated monocytes/macrophages in the
gut lamina propria (192–194). Isolated peripheral blood and gut
CD41 T cells from Crohn’s disease patients made IL-17 upon
stimulation with phorbol myristate acetate and ionomycin in
vitro, with almost 40% of the IL-17-producing T cells in the gut
also expressing IFN-g (17). Biopsies of inflamed colonic tissue
from patients with either Crohn’s disease or ulcerative colitis
expressed IL-17 at the mRNA level and CD41 Th17 cells were
found clustered in the lamina propria (195). In a separate study,
CCR91 T cells isolated from the lamina propria of Crohn’s disease
patients produced high levels of IL-17 when restimulated in
vitro, but CCR91 T cells from healthy individuals did not
produce IL-17 (196). IL-22, a putative product of human
Th17 cells, was also found to be overexpressed by colonic
CD41 T cells in patients with IBD compared with healthy
controls (48). Thus, the intestinal lamina propria appears to be an
inductive site for human Th17 cells during IBD.
The effector functions of IL-17 and IL-22 in the inflamed
human intestine are just beginning to be studied. IL-17A
induced the expression of G-CSF from human peritoneal
mesothelial cells, a mechanism that promotes the
accumulation of polymorphonuclear neutrophils in the
peritoneum (197). The G-CSF-inducing effect of IL-17A on
mesothelial cells was synergistic with TNF-a and was mediated
through activation of NFkB (197). IL-17A and IL-17F, but not
other IL-17 family members, have been shown to stimulate
MMP production and the release of pro-inflammatory
cytokines, such as IL-6, IL-8, and leukemia inhibitory factor
(LIF), from cultured primary human colonic subepithelial
myofibroblasts (SEMF) (198). Optimal induction of
inflammatory mediators was only achieved at concentrations
of IL-17A and IL-17F above 500 ng/ml, suggesting that
intimate contact between Th17 cells and SEMF might be
required for these effects in vivo (198). The levels of cytokines
and MMPs induced by IL-17A and IL-17F (500 ng/ml) alone
were several fold lower than those induced by either IL-1b
(10 ng/ml) or TNF-a (100 ng/ml), but both IL-17 family
members acted cooperatively with IL-1b and TNF-a to
enhance IL-6, IL-8, MMP-1, and MMP-3 expression in SEMF
cells (198). Very similar results were obtained when IL-22 was
used to stimulate primary human SEMF (48). In addition to the
above-listed MMPs and inflammatory cytokines, IL-22 was
shown to induce IL-11, MMP-10, and several neutrophil-
attracting chemokines (48). IL-22 was also found at higher
levels than IL-17 or IFN-g in the serum of patients with Crohn’s
disease and induced secretion of LPS-binding protein from
cultured human hepatocytes, a mechanism that may protect
Crohn’s disease patients from LPS-mediated systemic
inflammation (199). IL-17 also inhibited the proliferation of
cultured human intestinal epithelial cells, an important repair
mechanism needed to maintain epithelial integrity (200). In
the same study, the combination of TNF-a and IFN-g potently
induced intestinal epithelial cell apoptosis, while IL-17 had no
effect on cell death (200). Yet the combination of IL-17, TNF-a
and IFN-g, the latter being co-produced by Th17 cells in the
intestine, would be expected to elicit damage to the epithelial
barrier that would not be repaired by epithelial cell
proliferation.
Taken together, these findings suggest that Th17 cells and the
inflammatory mediators that either induce them (IL-1b, IL-6,
and IL-23), act in concert with IL-17 (TNF-a and IL-1b), or
work downstream of IL-17 to mediate gut inflammation (G-
CSF, chemokines, and MMPs) are all attractive targets for
treatment of IBD. Treatment with TNF blockers, IL-23
inhibitors, IL-1 receptor antagonist, or anti-IL-6 may soon
become the standard of care for IBD patients (190, 191, 201,
202). Interestingly, other emerging treatments that have shown
clinical efficacy, such as apheresis and dietary modifications,
have resulted in reduced mucosal concentrations of IL-1b, IL-
6, and IL-8 suggesting possible effects on human mucosal
Th17 cell development and function (203, 204).
Periodontal disease
Periodontitis and gingivitis are initiated by Gram-negative
bacterial infections in the mouth and are mediated, in part, by
activation of CD41 and CD81 T cells (205). Significant
parallels between the disease pathogenesis of periodontitis
and RA suggested that IL-17 might be a key contributor to
periodontal disease (205, 206). Stimulation of PBMCs col-
lected from patients with gingivitis and periodontitis by the
outer membrane protein (OMP) of Porphyromonas gingivalis, a
causative microorganism in periodontal disease, led to OMP-
induced expression of IL-17 (207). Comparison of IL-17
mRNA expression from freshly excised gingival tissue and
peripheral blood of the same patients revealed that, in the
majority of cases, IL-17 expression was much higher in
gingival tissue (207). Subsequent studies have confirmed the
presence of IL-17 in inflamed gingival tissues (208–210), and
one report showed that levels of IL-17 were high at an
intermediate stage of disease progression and then returned to
baseline levels in patients with more severe lesions (208). In
contrast, peak levels of IL-11 were reached earlier in disease
than IL-17, whereas levels of IL-6 and RANTES were highest in
severe disease (208). However, a recent follow-up study by the
same group showed that levels of IL-17, IL-23, IL-1b, IL-6, and
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TNF-a were highest in the most severe sites of inflammation,
but this difference may be attributable to a change in the
definition of severity (211). In a separate study, immunocyto-
chemistry revealed that the frequencies of cells staining positive
for IL-1b, TNF-a, and IL-17 were 5.0-, 3.9-, and 6.2-fold
higher in gingival tissue from periodontitis patients than in
healthy controls (212).
Culture supernatants of unstimulated gingival tissue and
T-cell lines derived from gingiva of periodontitis patients were
positive for IL-17 protein and mRNA, respectively (210, 213).
Similar to the findings in inflamed gingival tissues, IL-17 was
found in the deeper, surgically removed, periapical lesions of
patients that showed signs of periapical alveolar bone loss by
radiography (214). IL-17 levels in the periapical tissue directly
correlated with levels of IL-8, and IL-17 stimulation of
mononuclear cells from peripheral blood and periapical
lesions of symptomatic patients resulted in dose-dependent
increases in IL-8 production by mononuclear cells (214).
The role of IL-17 in mediating periodontal disease seems to
parallel the roles attributed to IL-17 in RA and other diseases.
Human gingival fibroblasts were stimulated to secrete IL-6
upon activation with recombinant IL-17, an effect that was
neutralized by addition of anti-IL-17 antibody (209, 212). IL-
17 also directly induced gingival fibroblasts to produce IL-8
and modest amounts of proMMP-1 and MMP-3, as well as
inducing IL-1b and TNF-a production from healthy, adherent,
PBMCs (212). IL-1b and TNF-a were potent stimulators of
MMP expression by gingival fibroblasts, thus IL-17 may have
direct and indirect roles in the production of MMPs in
periodontal disease (212).
These findings suggest that blockade of the IL-17 axis could
be a potential treatment option in periodontal disease.
However, strong caution is warranted in this disease setting,
because IL-17 has known important functions in the control of
Gram-negative bacterial infections such as those that cause
periodontitis. Proof of the danger involved in blocking IL-17 in
the mouth comes from a study of P. gingivalis infection in IL-17
receptor A-deficient mice in which periodontal bone
destruction was exacerbated (215).
Th17 cells in host defense against infection
Bacteria
Little direct information exists regarding the importance of IL-
17 and Th17 cells in resistance to infection in humans. Such
knowledge is critical, as clinical interventions to regulate or
neutralize IL-17 are likely to be tested in the near future. Much
more is known in the mouse, which, despite obvious environ-
mental and genetic differences from human, has often been a
reliable species to indicate infectious risks attendant upon
neutralization of cytokines, for example TNF.
Relevant genetic defects in humans are confined to rare
individuals with homozygous mutation of either the IL12B
gene, which encodes the p40 subunit common to IL-12 and IL-
23, or the IL12BR1 gene, which encodes a subunit of the IL-12
and IL-23 receptors (216). Infectious difficulties in these
individuals are mainly due to mycobacteria and salmonella,
and this occurrence has been attributed to the Th1 deficiency
rather than Th17 deficiency. It has therefore been inferred that
IL-17 might not have an important role in protection against
pathogens (217), which, if true, would be an important
advantage for approaches to human autoimmune disease that
employ IL-17 inhibition. Considerable caution is warranted,
however, in extrapolating observations from IL-23-deficient
states to the anticipated consequences of IL-17 blockade,
because Th17 cell development is supported by cytokines
other than IL-23, and the role of IL-23 in Th17 development
and expansion appears to be at least partly redundant.
Deficiency of tyrosine kinase 2 (tyk2), which is required for
signaling through IL-23R, has been reported to lead to
susceptibility to multiple infections in the context of hyper-
immunoglobulin E syndrome (218). However, tyk2 is involved
in signal transduction by multiple cytokine receptors,
including those for IL-12, IFNs, IL-6, and IL-10, as well as IL-
23, so that effects on Th17 cells are unlikely to underlie all of
the immune aberrations in such patients.
In mice, there is considerable evidence that IL-17 and/or IL-
23 are important in host responses to infection by Gram-
negative bacteria, specifically Klebsiella, Pseudomonas, Escherichia coli,
Salmonella, and Bordetella species. This role is not solely due to
generation of an adaptive Th17 response but also reflects innate
immune properties of IL-23 and IL-17. For example, Toll-like
receptor 4 (TLR4) triggering by E. coli LPS can lead to rapid
release of IL-23, which induces prompt release of IL-17 by gdT
cells. IL-17 from gdT cells peaks at 6 h in locations such as the
peritoneal cavity, resulting in a subsequent influx of
neutrophils within 24 h (219). Neutrophil chemotaxis
induced by IL-17 is primarily indirect, and IL-17 can induce
chemokine production by peritoneal mesothelial cells (220).
IL-17 can also induce release of G-CSF, which increases
neutrophil production in the bone marrow (221). In
leukocyte function-associated antigen-1 (LFA-1)/ mice
(a model for a human immunodeficiency), both G-CSF and
IL-17 are strikingly elevated compared with LFA-11/ mice.
LFA-1/ mice have neutrophilia and are resistant to
intravenous infection with Listeria monocytogenes, due to
enhanced neutrophil infiltration of organs such as the liver
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(222). These unexpected results provide an unusual example
of resistance to a specific infection as a consequence of an
immunodeficiency. The data also indirectly suggest that LFA-1
signaling could exert a negative effect on IL-17 production and
that neutrophilia in LFA-1 deficiency is not due solely to
ongoing infection.
IL-17 induction of neutrophil chemotaxis is important in
defense against a variety of organisms that infect the lung, such
as Klebsiella pneumoniae. In mice infected with this organism, TLR4
expression in the lung leads to production of IL-23 by DCs,
which then stimulates both CD41 and CD81 lymphocytes to
release IL-17 (223). Endotoxin alone, when introduced into
the respiratory tract, can initiate an IL-17-dependent pathway
that leads to neutrophil influx (224, 225). When mice are fed
ethanol, a risk factor for aggressive pulmonary infection by
Klebsiella in humans, release of IL-17 and recruitment of
neutrophils in the lung is suppressed, and mortality is
enhanced (226). Local gene therapy for IL-17 restores IL-17
production and survival in this system. Likewise, in mice
infected with Mycoplasma pneumoniae, infiltration of the lung by
neutrophils is dependent upon IL-23-induced upregulation of
IL-17A and IL-17F (227).
The important respiratory pathogen Bordetella pertussis, the
cause of whooping cough, employs multiple pathways to
elicit an IL-17 response. Protection of mice by the pertussis
vaccine requires production of IL-23, IL-1, and IL-17, and
generation of these cytokines is dependent on TLR4 on APCs.
IL-17 then activates macrophage killing of B. pertussis. A Th1
response, along with a Th17 response, may be necessary for
optimal immunity to this organism (228). In addition,
pertussis toxin enhances Th17 differentiation while
suppressing Treg generation or function, through induction
of IL-6 production (229).
Another very important respiratory pathogen in humans is
Streptococcus pneumoniae, and antibody responses to capsular
polysaccharides are believed to be critical in host defense
against natural infection, as well as in the protective immunity
induced by the pneumococcal vaccine. In a mouse model of
intra-nasal pneumococcal vaccination, protective immunity
could be induced in agammaglobulinemic animals in an IL-
17-dependent manner (230). These results imply that at least
some Th17 cells recognize carbohydrate antigens. Consistent
with this concept, IL-17 was required for formation of intra-
abdominal abscesses in response to Bacteroides fragilis or
polymicrobial cecal contents, a process dependent upon
recognition of bacterial polysaccharides by CD41 T cells.
Abscess formation required T-cell costimulation by the CD28-
B7 pathway and was compromised in STAT4/ animals (231,
232). Survival in the face of intra-abdominal sepsis can
potentially be enhanced by concurrent triggering of TLR9
by CpG oligodeoxynucleotides, and in a rat model, this
effect was found to be dependent upon IL-17 and probably
IL-23 (233).
A variety of microbial products can thus lead to IL-17
production through both TLR-dependent and TLR-
independent pathways (234). Relevant TLR pathways include
those initiated by TLR4 and TLR9. The effects of TLR9 agonists
in promoting IL-17 and IFN-g production can be antagonized
by type I IFNs (128). The effects of TLR2 ligation on IL-17
production are more uncertain at this point. On one hand,
TLR2 ligands from a non-pathogenic bacterium robustly
stimulated IL-23 production (235). However, in a mouse
model of brain abscess due to Staphylococcus aureus, TLR2
knockout mice manifested increased IL-17 in the brain,
without effect on outcome or survival (236). Recently human
DCs were shown to use the intracellular NOD-2 receptor to
recognize the muramyldipeptide component of bacterial
peptidoglycan and respond by producing IL-23 and IL-1, that
in turn stimulated Th17 cell development (237). In the effector
phase of host defenses, the Th17 cytokines IL-17 and IL-22 can
stimulate tissue cells to produce a variety of anti-microbial
peptides (44).
In some circumstances, IL-23 and/or IL-17 may even be
associated with an unfavorable outcome of infection. For
example, neutralization of IL-23 promoted survival in a
mouse model of endotoxic shock induced by Pseudomonas
aeruginosa (238). These results, considered in context of the
multiple pro-inflammatory effects of IL-17 and IL-23 in the
lung (239), raise questions about a potential harmful role of
IL-23 and IL-17 in patients with cystic fibrosis, whose lungs
are frequently infected by Pseudomonas, an organism that is
associated with an adverse clinical course in this disease.
Indeed, IL-17 and IL-23 levels are elevated in the sputum of
patients with cystic fibrosis who are infected with Pseudomonas
(240). In mice challenged with this organism, IL-23p19/
animals had less pulmonary inflammation without an increase
in bacterial dissemination, leading the authors to suggest
consideration of therapeutic neutralization of IL-23 in cystic
fibrosis. The IL-17 response in Helicobacter pylori infection might
also contribute to deleterious inflammation of the stomach due
to induction of chemokines (241).
The role of IL-17 in the arthritis of Lyme disease, which is
caused by the spirochete Borrelia burgdorferi, illustrates the
complex effects of pro-inflammatory cytokines in syndromes
at the junction of infection and immune-mediated disease. An
early report that B. burgdorferi lipopeptides induced IL-17
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production by T cells via effects on APCs included the astute
observation that IL-17 could not be classified as either a Th1 or
a Th2 cytokine (242). Subsequently, it was shown that murine
APCs preferentially produced IL-23, rather than IL-12, upon
exposure to B. burgdorferi. Neutralization of IL-17 was shown
to be therapeutic in a murine model of Lyme disease (243),
in association with expansion of the Treg CD41CD251
population (244). Antigens derived from B. burgdorferi are
among a group of LPSs and glycolipids that induce IL-17 from
a subset of invariant NKT cells (245). More information is
needed about the sources and roles of IL-17 in human Lyme
disease.
Such examples of a deleterious role of IL-17 or IL-23 in the
outcome of bacterial infection are unusual, however. Although
the available data derive primarily from rodent models,
exposure of human monocytes to the Gram-negative bacterium
Francisella tularensis, the cause of tularemia, upregulated
expression of transcripts for the p19 subunit of IL-23 by 300-
fold and also led to a striking up-regulation of p40 transcripts
(246). It therefore should be assumed that the significant body
of work that has established a role for IL-17 in host defense
against bacteria, especially Gram-negative organisms, has
substantial implications for the potential use of IL-17
neutralization in the treatment of human disease, both in the
design of clinical trials and in subsequent use in broader
populations of patients.
Mycobacteria
The observation that TNF blockade in the treatment of RA and
IBD led to frequent reactivation of tuberculosis highlighted the
importance of understanding the role of a cytokine in control
of mycobacterial infections before undertaking its therapeutic
neutralization. Animal model systems have demonstrated the
essential role of TNF in host defense against tuberculosis. In
contrast, the role of IL-17 in animal models of tuberculosis is
far less clear or convincing. Although IL-23 can fortify lung
defenses against Mycobacterium tuberculosis (MTB) (247) and can
substitute for IL-12 in such responses (248), its primary role in
this setting seems to be the induction of IFN-g, with IL-17
production of lesser importance. In the absence of IL-12 or
IFN-g, the IL-23/IL-17 axis produces a neutrophilic pulmon-
ary infiltrate that is less effective in controlling MTB infection
(249). Indeed, upregulation of IL-17R expression is a char-
acteristic of mouse strains that show enhanced susceptibility to
MTB, in association with an exaggerated neutrophil influx at
the site of infection, whether pulmonary or peritoneal (250).
The source of IL-17 in murine MTB infection appears to be
primarily from gdT cells and other non-CD41 cell populations,
and induction of IL-17 by IL-23 occurs as early as 1 day into
infection, suggesting an innate rather than adaptive response
pathway (251).
In experimental Mycobacterium bovis (BCG) infection, absence
of IL-23 does not compromise control of infection and
neutralization of IL-17 has little effect, in the presence or
absence of IL-12. However, in the absence of IL-12, IL-23 plays
an important role as an inducer of a Th1 response (252).
Moreover, IFN-g regulates IL-17 production during BCG
infection, which could limit deleterious influx of neutrophils
(253). It has been reported that in the context of IL-17
deficiency the Th1 response in BCG infection is less robust
(254). As with MTB infection, IL-17 appears early, is
dependent on IL-23, and is produced by gdT cells instead
of CD41 T cells. Importantly, despite these observations,
mycobacterial numbers in various organs are not increased in
IL-17 knockout mice (254).
BCG is used as a live vaccine to partially control MTB
infection. Alternative strategies for induction of protective
immunity to MTB are also being explored. In mice
immunized with an MTB DNA vaccine, a protective response
was not seen in p40/ animals. Partial reconstitution of
either IL-12 or IL-23 by gene therapy using transfected
APCs was partially protective. In p40/ mice immunized
subcutaneously with BCG and later challenged with MTB,
an IL-23-independent induction of an IL-17 response was
observed in lymph nodes but not in lung tissue, which
correlated with a reduced mycobacterial load in the lung
(255). Furthermore, vaccination of mice with a peptide
derived from the mycobacterial antigen ESAT-6 (6 kDa early
secreted antigenic target protein) induced an accelerated and
protective Th1 response that required IL-23 and IL-17. This
result was postulated to reflect early influx of Th17 cells into
the lung, which engendered production of chemokines that
efficiently recruited CD41 cells, which then mediated a Th1
response (256). However, the ESAT-6 protein, which binds to
Toll-like receptor-2 (TLR-2), has also been shown to inactivate
other TLR signaling pathways and truncate the innate immune
response to mycobacteria (257).
The available data suggest that neutralization of IL-17 would
be unlikely to paralyze host defenses against mycobacteria,
although more data are needed in models of reactivation of
latent infection. However, neutralization of p40, an approach
already in use in human immune-mediated diseases, could be
problematic because of simultaneous compromise of both Th1
and Th17 immunity. Furthermore, strategies that interfere with
IL-17 might perturb the response to mycobacterial vaccines in
ways that are currently difficult to anticipate.
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Fungi and other opportunistic pathogens
In a mouse model of infection with the fungal organism
Cryptococcus neoformans, the IL-23/IL-17 axis was shown to have
a significant role in host defense, although Th1 responses were
more important (258). Likewise, a protective role for IL-23
and IL-17 was documented in a mouse model of Pneumocystis
carinii lung infection (259). In contrast, the role of IL-17 in host
defense against the fungal pathogen Candida albicans is contro-
versial. Mice lacking the IL-17A receptor had reduced survival
following intravenous injection of this organism, and gene
therapy with IL-17 (IL-17A) enhanced survival of normal mice
(260). In contrast, IL-23p19/ mice had enhanced survival
upon challenge with C. albicans or Aspergillus fumigatus, while
p35/ mice were even more susceptible than p40/ mice
(261). Moreover, IL-23 and IL-17 were shown to directly
suppress the ability of neutrophils to kill candidal organisms
(261). These findings led to the conclusion that IL-23 and
IL-17 had a largely deleterious role in host defense against
fungi (261, 262).
However, human memory T cells responsive to C. albicans
were found to reside mainly in the Th17 subset, in contrast to
memory T cells for MTB, which were mostly Th1 (43).
Interestingly, C. albicans yeast induced human DCs to produce
primarily IL-12, while C. albicans hyphae induced IL-23
exclusively (43). The candidal b-glucan curdlan was shown to
induce mouse DCs to produce IL-23 by a non-TLR pathway,
through binding to dectin-1 (263). This finding indicates
that triggering of specific pattern recognition receptors on
APCs could skew immune responses to Th17 versus Th1
pathways (264).
These apparently paradoxical results highlight the
complexity of fungal infections and the host response to such
pathogens. Issues to consider include differences between
hyphal and yeast forms of the organism, possible differences
in host responses in mice versus humans, and subtle differences
between the consequences of the various genetic manipu-
lations used in the mouse systems. IL-17R-deficient mice,
for example, might lack responses to other cytokines in the
IL-17 family beyond IL-17A, while IL-23-deficient mice
could still develop Th17 cells. Understanding whether
Th17 cells are important in anti-fungal immunity is of
significant practical importance, as organisms such as
Pneumocystis, Candida, and Cryptococcus are common opportunistic
pathogens in immunosuppressed patients. A reasonable
synthesis of current information would suggest that limited
and correctly timed Th17 responses are protective, when
appropriately balanced with concurrent Th1 immunity, but
that uncontrolled Th17 cell activity could lead to a counter-
productive level of organ inflammation. A similar suggestion
has been made regarding the role of Th17 cells in host defense
against Toxoplasma gondii, an obligate intracellular organism that is
an important human pathogen in human immunodeficiency
virus-infected individuals, newborns, other immuno-
compromised subjects, and sometimes in people who are
otherwise apparently healthy (265).
Parasites
Parasitic infections are especially common and problematic in
economically disadvantaged societies. The helminth Schistosoma
mansoni can lead to serious granulomatous inflammation in the
liver. In a murine model system of schistosomal hepatic
inflammation, IL-17 was found to be highly pathogenic,
especially in the absence of IFN-g in IL-12p35/ mice
(266). More studies are needed concerning the Th17 response
in humans naturally infected with parasitic organisms.
Viruses
Herpesvirus saimiri, which can infect and transform T lymphocytes
from non-human primates, carries a variety of mammalian gene
homologs in its genome, including genes that encode viral forms
of IL-17 and the IL-8R (4, 267). The viral IL-17 is functionally
similar to mammalian IL-17 and indeed was used to first identify
the IL-17R (4). IL-17 is not required for the transforming ability
of H. saimiri (268). Human viruses are not known to encode an
IL-17 gene, but several can induce IL-17 responses, including
herpes simplex (269), respiratory syncytial virus (RSV) (270,
271), rotavirus (272), and human T-cell leukemia virus type 1
(HTLV-1) (273). In the case of HTLV-1, the viral Tax protein,
produced by infected T cells, activates the IL-17 gene promoter
by engaging the CREB/ATF pathway (273). In human immuno-
deficiency virus infection, production of IL-17 by peripheral
blood T cells is enhanced compared with control subjects,
although the cause and significance of this phenomenon is not
yet known (274). Exogenous IL-17 exaggerates the inflamma-
tory response to rhinovirus (275) or vaccinia virus (276),
leading in the latter instance to accelerated mortality. The pro-
inflammatory effects of IL-17 in herpes simplex virus or RSV
infections were also inferred to be detrimental overall to the
host. Examples are not yet available with human pathogens that
demonstrate a primary role for Th17 rather than Th1 responses
in anti-viral host defenses. Rather, the role of Th17 cells in viral
infections seems to be either secondary or even pathogenic.
Th17 cells and cancer
Information from both experimental animal systems and hu-
man cancer patients suggests that IL-17 and IL-23 are generally
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favorable to the growth of tumors and that these effects
outweigh their roles in the generation of T-cell anti-tumor
immunity. Studies in nude mice showed that transfection of
cervical carcinoma cell lines with an IL-17 cDNA led to faster
growth in vivo (277). Human ovarian cancer specimens that
contained IL-17 exhibited significantly greater angiogenesis
(278). In general, IL-17 present in tumors is not believed to be
secreted by the tumor cells themselves, with the exception
of cutaneous T-cell lymphoma cells, which secrete IL-17
(279), and possibly also some pancreatic cancers (280).
However, it is likely that most types of tumor cells express
IL-17 receptors, as has been well documented in prostate
cancer (281). In addition to angiogenesis, IL-17 can promote
neutrophilic invasion of tumors (282). These inflammatory
and pro-angiogenic effects of IL-17 are mediated by local
production of cytokines and chemokines, by the tumors
themselves (283) or more typically by adjacent tissue, stromal,
and/or inflammatory cells (279, 284, 285). When lung cancer
cell lines were transfected with an IL-17 cDNA, in vitro growth
was not altered, but in vivo growth in severe combined
immunodeficient mice was accelerated. The tumor cells them-
selves were induced to secrete multiple angiogenic, not angio-
static, factors by IL-17, and neutralization of CXCR-2 abrogated
the tumor-promoting effect of IL-17 in vivo. Furthermore,
human lung cancer specimens that contained IL-17 had a
higher vascular density on histologic analysis than those devoid
of IL-17 (285).
In some model systems in immunocompetent mice,
expression of IL-17 boosts anti-tumor immunity by
contributing to the development of cytotoxic T cells (286,
287). However, in human patients with advanced ovarian
cancer, Th17 cells are increased in number in the blood and
especially in tumor tissue or exudates and coexist in the tumor
specimens with even larger numbers of Treg cells and with
some CD81IL-171 cells (288). The authors of this report
inferred a pathogenic role for IL-17 in cancer.
In experimental systems, IL-23 can also have striking tumor-
promoting activity. In IL-12 knockout mice in which skin
tumors were induced by ultraviolet irradiation, local
inflammation, tumor proliferation, and expression of IL-6 and
IL-23 were all significantly enhanced compared with wildtype
controls (289). IL-23, but not IL-12, was shown to be
overexpressed in human colon cancers (290). In a mouse
system of cutaneous chemical carcinogenesis, IL-23-deficient
mice were protected, while IL-12-deficient mice were
especially susceptible, and protection against tumor growth
correlated with CD81 T-cell infiltration (290). Growth of a
variety of established tumor lines in mice was also reduced by
genetic deletion or antibody neutralization of IL-23 (290). It
was further suggested that IL-23 might directly inhibit the
ability of cytotoxic T cells to infiltrate tumors (291), although
much more work is needed to adequately test this hypothesis.
In contrast, IL-23, like IL-17, has unequivocal anti-tumor
effects in some experimental systems that are mediated by
cellular immune responses against the tumor (292). Fully
satisfactory explanations for the contradictory data cited above
regarding the roles of IL-17 and IL-23 in cancer are not yet
available. It is possible that the effects of these cytokines will
vary with different tumors, which may be associated with
distinct patterns of stromal, angiogenic, and inflammatory
reactions. The timing and dosage of introduction of IL-17 or
IL-23 into tumor systems, and the balance with Th1 immunity
and other aspects of host defense, could also be critical.
Th17 cells and transplantation
Evidence is accumulating for an important role of IL-17 in
allograft rejection, both in rodent models and in humans. IL-17
is specifically present in kidneys undergoing rejection, both in
rats and in humans (293–295). IL-17 is not found in normal
kidneys or in transplants not undergoing rejection. Moreover,
it is present early, and its appearance is soon followed by the
local production of pro-inflammatory molecules known to be
induced by IL-17. IL-17 mRNA in urinary sediment may be an
early and sensitive indicator of otherwise unapparent early
renal allograft rejection (294, 295). In both rat and human
lung transplants, late damage to the allograft was found to be
associated with and likely mediated by autoreactive Th17 cells
specific for type V collagen that engender bronchiolitis obliter-
ans (296, 297). In mouse and rat cardiac allograft models, use
of a soluble IL-17R protein prolonged graft survival (298,
299). These findings help to provide a conceptual basis for
therapeutic interference with Th17 cells in human organ
transplantation.
Conclusion
Although information about human Th17 cells has lagged
slightly behind the avalanche of new data from murine
systems, it is clear that IL-17 is likely to be a cytokine of
significant and potentially central importance in a diverse
spectrum of human diseases. More data are needed regarding
functional subsets within the Th17 cell population, the nature
of the overlap between Th1 and Th17 cells, and the pathways
by which Th17 responses are regulated in the human immune
system. Much more needs to be learned about IL-17 produc-
tion by non-CD41 cells and about the functional importance
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of the other members of the IL-17 family, beyond IL-17A.
As strategies to interfere with Th17 function enter clinical
trials in immune-mediated human diseases, careful scrutiny
must be given to any deleterious effects on host defenses.
While some predictions and suggested precautions can be
inferred from available information, additional lessons will
inevitably be learned in the course of clinical research
in human subjects.
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